Plain-English translation of NCT04952480 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new way to deliver radiation therapy for small cell lung cancer. Instead of using one fixed radiation plan for the entire treatment, doctors will create adjusted plans twice during your therapy—at week 1 and week 2—to match how your tumor shrinks. You'll receive this adaptive radiation therapy together with standard (cisplatin and etoposide) over 5 to 7 weeks.
Small cell lung cancer is aggressive and hard to treat. Researchers believe that by increasing the radiation dose and adjusting the plan as the tumor shrinks, they can improve how well the treatment works while still protecting healthy organs nearby.
You likely qualify if…
You likely don't qualify if…
You'll receive and radiation therapy together over 5 to 7 weeks. The radiation plan will be adjusted twice—after your first week of treatment and after your second week—based on CT scans showing how your tumor is responding. You'll have follow-up visits and scans for 24 months after treatment ends to monitor how well the treatment worked and check for any side effects.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
Canada
Phase
Testing effectiveness
Sponsor
AHS Cancer Control Alberta
Enrollment target
~31 participants
Started
June 2022
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yee Don, MD
Cross Cancer Institute, Alberta Health Services
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.